Standard Biotools Inc. · NASDAQ:LAB
Standard Biotools — Fluidigm — IPO Roadshow (January 2014)
17 slides from Standard Biotools's IPO roadshow presentation, Jan 29, 2014
Slide 1: Acquisition of DVS Sciences
Acquisition of DVS Sciences January 29, 2014 ANNEX B
Slide 2: Transaction overview
Transaction overview Purchase Price $207.5 million Structure $125 million cash (~60% of Price) $82.5 million FLDM stock (~40% of Price)* Collar +/- 10% collar to FLDM trading price* at signing Financing Fluidigm stock and additional cash expected to be raised through a proposed convertible notes off
Slide 3: Combination creates a single-cell technology powerhouse
Combination creates a single-cell technology powerhouse
Slide 4: DVS Sciences' mass cytometry technology enables multi-parameter single-cell protein analysis
DVS Sciences’ mass cytometry technology enables multi-parameter single-cell protein analysis.
Slide 5: DVS Sciences product portfolio
DVS Sciences product portfolio Source: DVS Sciences’ CyTOF2 Brochure
Slide 6: Addressable high-end research flow cytometry market segment of $300 million in 2013
Addressable high-end research flow cytometry market segment of $300 million in 2013 Global research flow cytometry market of $1.5 billion in 2013, growing at a CAGR of ~10%. High- end, $300M Source: BCC Research October 2013, Fluidigm internal estimates Note: High-end segment includes instrument, re
Slide 7: Limitation of traditional flow cytometry
Limitation of traditional flow cytometry Severe signal overlap complicates high parameter panel development
Slide 8: CyTOF technological advantage
CyTOF technological advantage Ability to detect and quantify up to 34 parameters simultaneously in a single cell with headroom for expansion. (stable isotope) mass La Pr Nd Sm Eu Tb Gd Ho Er Tm Yb Lu Ba Dy 14 elements: 30 isotopes
Slide 9: Higher number of parameters drives new insight
Higher number of parameters drives new insight 4-8 color 30-50 parameters Today’s Fluorescent Flow Reality Today’s Mass Cytometry Reality
Slide 10: Complementary single-cell analysis product portfolio
Complementary single-cell analysis product portfolio BioMark C 1 + NGS CyTOF2 # single cells per experiment 1,000 10K 100K 1M 10M Targeted GX WGS WES Targeted DNASeq mRNA Seq Epigenetics Proteins DVS Sciences’ CyTOF technology expands the throughput and analytical breadth of our single-cell analysis
Slide 11: Summary of facilities and offices
Summary of facilities and offices DVS Sciences Facilities Fluidigm Facilities • Sunnyvale, CA Facility (Corporate HQ) – – Reagent manufacturing (pre-conjugated antibody and conjugation kits) – West coast and Asia demo and training • Toronto, Canada Facility – – Instrument manufacturing – Instrument
Slide 12: Fluidigm's global commercial footprint
Fluidigm’s global commercial footprint – 25 sales and support in US and Canada – 15 sales and support in Europe – 12 distributors – 4 sales and support in Japan – 5 sales and support in China – 4 sales and support in Asia-Pacific and Latin America – 9 distributors – 14 HQ global support
Slide 13: DVS Sciences revenue ramp
DVS Sciences revenue ramp Millions of dollars 133% growth 5.1 11.9 18.5 123% growth 8.3 Q1-Q3 2012 Q1-Q3 2013
Slide 14: Combined installed base approaching 1,000 units
Product Key application Installed Base at year end 2013 Combined installed base approaching 1,000 units BioMark HD Single-cell gene expression ~530 EP1 SNP genotyping Access Array Next-generation sequencing sample prep ~260 C Single-cell genomics sample prep ~130 CyTOF Multi-parameter single-cell pr
Slide 15: Pro forma combined product margins
Pro forma combined product margins Gross margin (%) 71% 58% 68% Note: Pro forma Combined Q1-Q3 2013 excludes amortization of intangibles and stock-based compensation of $7.3 million. 0% FLDM Q1 - Q3 Pr o forma Combined Q1 - Q3 DVS Q1 - Q3
Slide 16: Combination creates a single-cell technology powerhouse
Combination creates a single-cell technology powerhouse
Slide 17: Fluidigm
Fluidigm £;